



iSTAR Medical Expands Scientific Advisory Board *Expertise to Support STARflo™ Glaucoma Implant*

For Immediate Release

Seattle, WA (February 2, 2011)—Healionics subsidiary iSTAR Medical, pioneering the development of STARflo™ – a next generation Glaucoma implant, announced today that it has added Dr. Murray Johnstone to its Scientific Advisory Board.

Dr. Johnstone is a Professor of Ophthalmology at the University of Washington. He received his medical degree from Washington University and completed his residency at Harvard Medical School. He received a fellowship and trained at Harvard/Massachusetts Eye & Ear Infirmary in 1973, followed by a busy practice as a Glaucoma sub-specialist through 2009. Dr. Johnstone has over 200 publications and presentations in the field of medical and surgical management of glaucoma including special emphasis on understanding the mechanisms of aqueous outflow where he continues his research today.

"We are pleased that we were able to attract Dr. Johnstone to our Scientific Advisory Board given his very applicable expertise for our implant. We look forward to working with him," said Michel Alvarez, CEO of Healionics Corporation and Director General of iSTAR Medical.

About Healionics Corporation

Healionics is a biomaterials technology company whose flagship STAR® Biomaterial aims to solve the historic "device-to-tissue" interface problem of long-term medical implants. Better healing and functioning implants are key to improving patient well-being while reducing the ballooning \$50 billion per year in global healthcare costs attributed to implant failures. STAR Biomaterial has shown promising results in reducing fibrosis, enhancing biointegration, and resisting infection, addressing several common causes for failure of long-term implants. For more information, please visit <http://www.healionics.com>.

About iSTAR Medical

iSTAR Medical SA is a Belgium-based spinout of Healionics Corporation. Its mission is to improve the lives of patients suffering from eye diseases and disorders. iSTAR's initial focus is to develop ophthalmic implants made from STAR Biomaterial for treating glaucoma and corneal blindness. www.istarmed.com

###

Contact:
Julie Rathbun
Rathbun Communications, Inc.
(206) 769-9219
Julie@rathbuncomm.com